Biobanking and Biomarker Validation (BBV) Core

生物样本库和生物标志物验证 (BBV) 核心

• 批准号: 10582682
• 负责人: ANDREW K. GODWIN
• 金额: $ 24.2万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-02-15 至 2024-04-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10582682
• 关键词: Accreditation; Area; B-Lymphocytes; BRAF gene; Benign; Biological Assay; Biological Specimen Banks; Biomedical Engineering; Biomedical Research; Blood; Blood specimen; Body Fluids; CLIA certified; Cancer Center; Caring; Cell Line; Cells; Centers of Research Excellence; Clinical; Clinical Research; Clinical Trials; Collection; Communities; Core Facility; Custom; DNA; Development; Diagnosis; Disease; Ensure; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor Receptor; Evaluation; Event; FLT3 gene; Faculty; Family history of; Fostering; Fresh Tissue; Funding; Future; Genes; Genomic DNA; Genomics; Goals; Healthcare; Histology; Human; Immunoassay; Immunohistochemistry; Individual; Informed Consent; Infrastructure; Institution; Interdisciplinary Study; Intervention; Irrigation; JAK2 gene; KRAS2 gene; Kansas; Laboratories; Length; Liquid substance; Malignant Neoplasms; Measurement; Medical center; Messenger RNA; Methylation; MicroRNAs; Microsatellite Instability; Mission; Molecular; Molecular Diagnostic Testing; Mutation Analysis; Needs Assessment; Nose; Nucleic Acids; Participant; Pathologic; Patients; Plasma; Pleural; Population; Proteins; Research; Research Personnel; Residual Neoplasm; Resources; Role; Saliva; Sampling; Science; Serum; Services; Somatic Mutation; Specimen; T cell clonality; Technical Expertise; Testing; Tissue Stains; Tissues; Universities; Urine; Western Blotting; Whole Blood; Work; active duty; base; bcr-abl Fusion Proteins; biobank; biomarker development; biomarker discovery; biomarker validation; cell free DNA; cost effective; design; exosome; extracellular vesicles; genetic signature; human leukocyte antigen testing; improved; improved outcome; innovation; lifestyle factors; malignant breast neoplasm; molecular diagnostics; molecular oncology; next generation sequencing; personalized care; pre-clinical; precision medicine; prognostic; programs; promoter; relative cost; repository; research clinical testing; research study; success; telomere

COBRE Kansas Institute for Precision Medicine (KIPM) – “Biobanking and Biomarker Validation Core” ABSTRACT The overall objective of the “Kansas Institute for Precision Medicine” (KIPM) COBRE at the University of Kansas Medical Center (KUMC) is to advance the customization of healthcare through promoting innovative scientific discoveries. We have entered the era of Precision Medicine, an initiative recently announced as part of the 21st Century Cures Act, which is focused on using the molecular basis of diseases to better match patients with the appropriate therapies and care resulting in improved outcomes. To advance this mission, we have established the Biobanking and Biomarker Validation (BBV) Core, which combines exceptional expertise and essential resources within established infrastructure, i.e., Biospecimen Repository Core Facility (BRCF), the Biomarker Discovery Laboratory (BDL), and the Clinical Molecular Oncology Laboratory (CMOL). Access to the BBV core will strengthen the biomedical research capacity of our COBRE faculty by enhancing their research base and infrastructure capacities. To advance precision medicine research within this COBRE, the BBV core will 1) Provide centralized and uniform collections, processing, and storage of tissue and bodily fluids and tissue-related histology services; 2) provide integral and comprehensive protein and nucleic acid isolation, quantitation, and molecular characterization services; and 3) provide fully customizable molecular testing and genomic-based sequencing services. The BBV core is designed to centralize these essential services that will in turn provide support to the KIPM COBRE faculty, pilot grantees, and researchers within our region and beyond. Given the level of sophistication of the materials and services required for the range of studies proposed within the KIPM COBRE, a highly integrated BBV core is not only cost effective but an absolute necessity. The BBV core eliminates redundant infrastructure and expense required for each researcher to develop their own capabilities or to search for the necessary research expertise. The BBV core will enable multiple COBRE faculty and future pilot grantees, access to state-of-the-art facilities and laboratory expertise, thereby further reducing the relative cost of their studies. Furthermore, the BBV core will continue to provide in-kind technical staff-support and banking resources, which help the KIPM COBRE faculty to more effectively utilize their funding, both institutional startup and COBRE support. The success of the BBV core and ultimately the COBRE faculty is essential to advancing the mission of the KIPM to advance the customization of healthcare through promoting innovative scientific discoveries.

COBRE堪萨斯精准医学研究所（KIPM）-“生物库和生物标志物验证核心” 摘要 堪萨斯大学“堪萨斯精准医学研究所”（KIPM）COBRE的总体目标 医疗中心（KUMC）是通过促进创新的科学， 发现。我们已经进入了精准医疗时代，这是最近宣布的21世纪 《世纪治愈法案》，该法案的重点是利用疾病的分子基础，更好地将患者与 适当的治疗和护理，从而改善结果。为了推进这一使命，我们建立了 生物库和生物标志物验证（BBV）核心，它结合了卓越的专业知识和基本的 现有基础设施内的资源，即，生物样本库核心设施（BRCF），生物标志物 探索实验室（BDL）和临床分子肿瘤学实验室（CMOL）。进入BBV核心 将通过加强我们的COBRE教师的研究基础， 基础设施能力。为了在COBRE内推进精准医学研究，BBV核心将1） 提供组织和体液以及组织相关的集中和统一的收集、处理和储存 组织学服务; 2）提供完整和全面的蛋白质和核酸分离，定量， 分子表征服务;以及3）提供完全可定制的分子测试和基于基因组的 测序服务。BBV核心旨在集中这些基本服务， 支持KIPM COBRE教师，试点受赠人和我们地区内外的研究人员。鉴于 KIPM内建议的研究范围所需的材料和服务的复杂程度 COBRE，一个高度集成的BBV核心不仅具有成本效益，而且是绝对必要的。BBV核心 消除了每个研究人员开发自己的能力所需的冗余基础设施和费用 或寻找必要的研究专长。BBV核心将使多个COBRE教师和未来 试点受赠方，获得最先进的设施和实验室专业知识，从而进一步减少相对 他们的研究费用。此外，BBV核心将继续提供实物技术人员支持， 银行资源，这有助于KIPM COBRE教师更有效地利用他们的资金，无论是机构 启动和COBRE支持。BBV核心和最终COBRE教师的成功对于以下方面至关重要： 推进KIPM的使命，通过促进创新， 科学发现。